From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
References 1. Baccarani, M., et al. (2009). Response definitions and European Leukemianet management recommendations. Best Practice & Research Clinical Haematology, 22 (3): 331-341. https://doi.org/10.1016/j.beha.2009.10.001 2. Labani, S., et al. (2014). Care HPV cervical cancer screening demonstration in a rural population of north India. European Journal of Obstetrics & Gynecology and Repro- ductive Biology, 176 , 75-79. https://doi.org/10.1016/j. ejogrb.2014.03.006 3. Li, W., et al. (2021). Trends in molecular testing of lung cancer in the mainland People’s Republic of China over the decade 2010 to 2019. JTO Clinical and Research Reports, 2 (4), 100163. https://doi.org/10.1016/j.jtocrr.2021.100163 4. Amoy Diagnostics. (n.d.). AmoyDx® Pan Lung Cancer PCR Panel . Retrieved June 24, 2025, from Amoy Diagnos- tics website: https://amoydiagnostics.com/products/ amoydx-pan-lung-cancer-pcr-panel
Benefits include: • Glycerol-free, lyophilizable formats for cold- chain–free storage and transport • High sensitivity for detecting low-frequency mutations and circulating cell-free DNA (cfDNA) • Custom formulation services available to support regulatory alignment and OEM integration As the use of qPCR continues to expand in oncology—especially for decentralized testing, early detection, and global health programs— Meridian’s reagent solutions provide the backbone for assay developers aiming to scale precision diagnostics without compromising performance.
Webinar
Shaping the Future of Precision Oncology: A Comparative Analysis of qPCR, Targeted NGS, and Whole Genome Sequencing Explore how assay format influences sensitivity, turnaround time, and accessibility in precision oncology: Watch our expert-led webinar on demand and gain insights into qPCR, targeted NGS, and WGS applications in cancer diagnostics.
28 | GENengnews.com
Powered by FlippingBook